Miacalcic terápia lehetséges költségei és következményei a csontritkulás kezelésében

[1] Barefield E.: Osteoporosis-related hip fractures cost $13 billion to $18 billion yearly. Available at: www.ers.usda.gov/publications/foodreview/ jan1996/frjan96e.pdf. Accessed March 14, 2002
[2] Bors K, Kósa J, Borbély J, Tabák Á, Horváth Cs.: A kalcitonin orrspray életminőségre gyakorolt hatásának hazai vizsgálata osteoporosisban. Ca és Csont 2004;7(2) :53-9.
[3] Cooper C, Campion G, Melton LJ.: Hip fractures in the elderly: a worldwide projection. Osteoporosis Int. 1992;2: 285–9.
[4] Dolan P, Gudex C, Kind P, Williams A. A: Social Tariff for EuroQol: Results from a UK General Population Survey. Centre for Health Economics, University of York, York, 1995.
[5] Gehlbach, et al.: Hospital care of osteoporosis-related vertebral fractures, Osteoporosis Int, 2003; 14:53-60.
[6] Gold, The Clinical Impact of Vertebral Body Fractures: Quality of Life in Women with Osteoporosis, Bone, 1996, 18:3:S185-189.
[7] Hays J., Ockene J. K., Brunner R. L. et al.: Effects of estrogen plus progestin on health-related quality of life. N. Engl. J. Med, 348, 19, 2003, 1839-54.
[8] Hodgson SF, Johnston CC.: AACE Clinical Practice Guidelines for the Prevention and Treatment of Postmenopausal Osteoporosis. Brandamore, PA: Herrin Communications; 1998.
[9] Hoerger TJ, Downs KE, Lakshmanan MC, et al.: Healthcare use among U.S. women aged 45 and older: Total costs and costs for selected postmenopausal health risks. J Womens Health Gend. Based Med 1999;8(8):1077-1089.
[10] Ishida Y, Kawai S.: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am J Med. 2004 Oct 15;117(8):549-55.
[11] Járay J, Kaló Z, Nagy J: Dialízis versus vesetranszplantáció összehasonlító költség-hatékonysági elemzés, 10.2 fejezet Gulácsi L: Klinikai kiválóság című könyvében, Springer Orvosi Kiadó Kft, 1999.
[12] Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jönsson B.: Intervention thresholds for osteoporosis. Bone 2002;31(1):26-31.
[13] Kricsfalusy M., Somogyi P., Udvardy Cs., Horváth Cs.: Az osteoporosis eredetű törések magyarországi költségvonzatai. Ca és Csont 2000;3(3):118-123
[14] Maher AB, Salmond SW, Pellino TA.: Orthopaedic Nursing. 2nd ed. Philadelphia, PA: Saunders; 1998.
[15] Morris R, Masud T.: Measuring Quality of Life in Osteoporosis Age and Ageing 2001;30:371-373
[16] Old J.L, Calvert M.: Vertebral Compression Fractures in the Elderly Am Fam Physician 2004;69:111-6
[17] Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis.Executive Summary. Osteoporosis Int 1998;8 (suppl 4): S3-S6.
[18] Owen R, Melton LJ 3rd, Gallagher JC, Riggs BL.: The national cost of acute care of hip fractures associated with osteoporosis. Clin Orthop 1980;150:172-176.
[19] Delmas P., Fraser M.: Strong Bones in Later Life: Luxury or Necessity? Bulletin of the World Health Organization, The International Journal of Public Health. Vol. 77, no.5, 1999. [20] Ray NF, Chan JK, Thamer M, Melton LJ.: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12(1):24-35.
[21] Riggs BL, Melton LJ.: The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(Suppl):505S–511S.
[22] Rossouw J. E., Anderson G. L., Prentice R. L. et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 17, 288, 3, 2002, 321-33.
[23] Russell LB, Gold MR, Siegel JE, et al.: The role of costeffectiveness analysis in health and medicine. JAMA 1996; 276: 1172-7
[24] Sherine E.G, Kneeland T.S, Melton L.G, Moncur M.M, Ettinger B, Tosteson A.: Health-Related Quality of Life in Economic Evaluations for Osteoporosis: Whose Values Should We Use? Medical Decision Making, 1999; 19 (2):141-148
[25] Skugor M, Licata A.: Osteoporosis Chapter of the Endocrinology Disease Area Cleveland Clinic Foundation 2004. http://www.clevelandclinicmeded.com/diseasemanagement/endocrinology/osteoporosis/osteoporosis.htm
[26] Somogyi P., Bossányi A., kricsfalusy M., Schreithofer L., Rápolthy I., Udvardy Cs., Horváth Cs.: Az osteoporoticus eredtű csonttörések számának becslése Magyarországon. Ca és Csont 2000;3 (3):111-117.
[27] Stergachis A.: Overview of cost-consequence modeling in outcomes research. Pharmacotherapy 1995; 15 (5 Pt 2): 40S-2S
[28] The Report on Osteoporosis in the European Community – Action for Prevention 1998.
[29] US Congress, Office of Technology Assessment. Evidence on benefits, risks and costs. In: Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Vol 2. Washington, DC: US Government Printing
[30] University of Washington Health Sciences and Medical Affairs: Study shows calcitonin-salmon nasal spray helps prevent new spinal fractures in women with existing osteoporosis [press release]. Seattle:; September 14, 1998. Office; 1995.
[31] Visentin P, Ciravegna R, Fabris F.: Estimating the costs per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 1997; 26(3):185-92
[32] Watts NB, Worley K, Solis A, Doyle J, Sheer R.: Comparison of risendronate to alendronate and calcitonin for early reduction of non-vertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm. 2004 Mar-Apr;10(2):142-51. IME IV. ÉVFOLYAM 1. SZÁM 2005. FEBRUÁR
[33] Williams A.: The Role of the EUROQOL Instrument in QALY Calculations. Centre for Health Economics, University of York, York, 1995.
[34] Zethraeus N, Ben Sedrine W, Caulin F, et al.: Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporosis Int 2002;13(11):841-857.